Drug intelligence / Profile preview

gorlizatini

Development stage: Unknown
Lead developer: Subei People's Hospital
Modality: Small Molecules
Administration: Oral

Overview

Gorlizatini is an investigational therapeutic agent being evaluated for the treatment of hematological malignancies. It has been specifically studied in the context of elderly, frail patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), a rare and aggressive subtype of peripheral T-cell lymphoma. The drug is currently being assessed in clinical case studies at institutions such as Northern Jiangsu People's Hospital to determine its efficacy and safety profile in patients who have failed standard therapies. While its precise molecular target and mechanism of action are not widely documented in public pharmacological databases, its nomenclature suggests it may function as a kinase inhibitor.

Other names: gorlizatini

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on gorlizatini.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gorlizatini.

Explore the full profile